Skip to main content

From the helm: Botanix Phamaceuticals (ASX:BOT) CEO, Dr Howie McKibbon

Bell Direct
October 9, 2024

In this episode of our From the helm series, Bell Direct’s Grady Wulff speaks with Dr. Howie McKibbon, CEO of Botanix Pharmaceuticals (ASX:BOT). Based in Philadelphia, Botanix is a dermatology company focused on advancing its lead product, Sofdra, which is FDA-approved for the treatment of primary axillary hyperhidrosis. With the successful commercialisation of Sofdra, the company is positioned in a growing market.

Dr. McKibbon joins us to discuss the latest developments and outlook for Botanix,. In this conversation, he covers:

  • (0:42) an overview of Botanix Pharmaceuticals for investors who may not be familiar with the company
  • (1:28) the significance of Sofdra’s FDA approval and the global market potential for its treatment
  • (2:48) the competitive landscape within the dermatology space
  • (3:45) how Botanix manages costs during the later stages of clinical trials and the factors contributing to its financial strength
  • (4:30) insights into what the next 12 months hold for Botanix.

Note: This interview was recorded at the ASX Small to Mid-Cap Conference on 25 September 2024.

Weekly Wrap 30 June

Grady Wulff
June 30, 2023

Morning Bell 30 June

Sophia Mavridis
June 30, 2023

Morning Bell 29 June

Grady Wulff
June 29, 2023

Morning Bell 28 June

Grady Wulff
June 28, 2023

Morning Bell 27 June

Grady Wulff
June 27, 2023

Morning Bell 26 June

Grady Wulff
June 26, 2023

Weekly Wrap 23 June

Grady Wulff
June 23, 2023

Morning Bell 23 June

Sophia Mavridis
June 23, 2023

Morning Bell 22 June

Sophia Mavridis
June 22, 2023

Morning Bell 21 June

Grady Wulff
June 21, 2023

Morning Bell 20 June

Grady Wulff
June 20, 2023

Morning Bell 19 June

Grady Wulff
June 19, 2023